Imatinib (Gleevec) detailed instructions and medication instructions analysis

1. Drug introduction and indications

Imatinib (Imatinib) is an oral targeted tyrosine kinase inhibitor (TKI) that selectively inhibits BCR-ABLtyrosine kinase, c-KIT and PDGFR and other signaling pathways can inhibit the proliferation of cancer cells. It is mainly used for the treatment of chronic myelogenous leukemia (CML), gastrointestinal stromal tumor (GIST) and other specific cancers. As the first generation of targeted drugs, imatinib has become one of the standard regimens for the treatment of CML, significantly improving patient survival rates and quality of life.

Imatinib indications include:

1.Chronic phase, accelerated phase and blast phaseCMLPatients;

2.Gastrointestinal stromal tumor (GIST) and the tumor has c-KIT or PDGFRα mutation;

3.Other BCR-ABL positive tumor patients who have been evaluated by doctors as suitable.

2. Dosage and taking method

Imatinib is an oral tablet, generally available in 100mg and 400mg specifications. Usual initial doses vary depending on the type of disease:

1.Chronic phaseCML: It is generally recommended to take 400mg daily once or in divided doses;

2.Accelerated phase or blast phaseCML: It can be increased to 600-800mg per day, and it needs to be taken in divided doses under the guidance of a doctor;

3.GIST: 400mg daily, which can be adjusted to 600mg if necessary.

Medication instructions:

1. Imatinib should be swallowed whole and should not be broken or chewed to avoid affecting drug absorption;

2. It can be taken with food or on an empty stomach, but to reduce gastrointestinal discomfort, it is recommended to take it with mild food;

3.Try to fix the medication time as much as possible and take it at the same time every day to ensure stable blood concentration;

4.If you miss a dose, you should take it as soon as possible. However, if it is close to the next dose, do not take it with a double dose.

3. Drug interactions and precautions

Imatinib is metabolized by the liverCYP3A4, so please pay attention to drug interactions during use:

1.Combined use with CYP3A4 inhibitors (such as ketoconazole, clarithromycin) may increase blood concentration and increase the risk of side effects;

2.Combined use with CYP3A4 inducers (such as rifampin, St. John's wort) may reduce the efficacy;

3. It should be used with caution in combination with anticoagulants, immunosuppressants or other anti-tumor drugs, and the dosage should be adjusted under the guidance of a doctor.

In addition, patients should pay attention to the following matters while taking the medication:

1. Regularly monitor blood routine, liver and kidney function and electrocardiogram to detect abnormalities early;

2.Avoid stopping the medication or increasing or decreasing the dose on your own to avoid affecting the efficacy;

3.If serious adverse reactions occur, such as persistent edema, bone marrow suppression or abnormal liver function, you should seek medical treatment in time.

4. Common side effects and treatment methods

Common side effects of imatinib include:

1. Blood system: anemia, decrease in white blood cells or platelets;

2.Gastrointestinal tract: nausea, vomiting, diarrhea or loss of appetite;

3.Others: edema, muscle spasm, rash or mild fever.

Treatment methods include:

1. Mild to moderate side effects can be alleviated by adjusting diet, rehydration or symptomatic drugs;

2. For severe side effects, the medication should be stopped and medical treatment should be conducted. The decision should be made whether to resume medication or adjust the dose based on blood routine and liver function;

3.Regular review to evaluate drug efficacy and tolerance to ensure continuity of treatment.

5. Storage and other precautions

Imatinib should be stored in a dry, dark, room temperature (15-30℃) environment, away from high temperature and humidity, and away from the reach of children. Tablets should not be broken into pieces or mixed with other drugs to avoid affecting stability.

In short, imatinib, as a targeted therapy, can significantly improve the survival rate and quality of life of patients with CML and GIST. Scientific and reasonable medication methods, strict monitoring and individualized dose adjustment are the keys to ensuring efficacy and safety. Patients should take medication under the guidance of a doctor, follow the instructions, and review regularly to maximize drug efficacy and reduce the risk of adverse reactions.

Reference materials:https://www.drugs.com/